Smithfield Trust’s AbbVie ABBV Stock Holding History

Smithfield Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.98M	Buy	32,099 +161	+0.5%	+$35.7K	0.3%	55
2025 Q4	$7.29M	Sell	31,938 -45	-0.1%	-$10.3K	0.32%	51
2025 Q3	$7.4M	Sell	31,983 -593	-2%	-$121K	0.33%	52
2025 Q2	$6.05M	Sell	32,576 -200	-0.6%	-$37.2K	0.29%	57
2025 Q1	$6.87M	Sell	32,776 -278	-0.8%	-$54K	0.34%	52
2024 Q4	$5.88M	Buy	33,054 +78	+0.2%	+$14.3K	0.29%	59
2024 Q3	$6.52M	Sell	32,976 -80	-0.2%	-$14.9K	0.32%	53
2024 Q2	$5.67M	Sell	33,056 -43	-0.1%	-$7.12K	0.3%	53
2024 Q1	$6.04M	Buy	33,099 +169	+0.5%	+$29.1K	0.32%	53
2023 Q4	$5.1M	Sell	32,930 -143	-0.4%	-$20.8K	0.29%	54
2023 Q3	$4.92M	Sell	33,073 -543	-2%	-$79.7K	0.3%	52
2023 Q2	$4.52M	Buy	33,616 +193	+0.6%	+$28.3K	0.27%	52
2023 Q1	$5.33M	Buy	33,423 +848	+3%	+$130K	0.34%	44
2022 Q4	$5.26M	Sell	32,575 -36	-0.1%	-$5.52K	0.35%	46
2022 Q3	$4.37M	Sell	32,611 -373	-1%	-$53.5K	0.32%	49
2022 Q2	$5.06M	Buy	32,984 +135	+0.4%	+$20.6K	0.36%	46
2022 Q1	$5.32M	Sell	32,849 -49	-0.1%	-$7.12K	0.34%	49
2021 Q4	$4.46M	Sell	32,898 -306	-0.9%	-$36.1K	0.28%	54
2021 Q3	$3.58M	Sell	33,204 -208	-0.6%	-$23.8K	0.24%	62
2021 Q2	$3.76M	Sell	33,412 -838	-2%	-$94.4K	0.25%	60
2021 Q1	$3.71M	Sell	34,250 -24	-0.1%	-$2.57K	0.26%	59
2020 Q4	$3.67M	Buy	34,274 +850	+3%	+$81.7K	0.27%	61
2020 Q3	$2.93M	Buy	33,424 +83	+0.2%	+$7.81K	0.24%	65
2020 Q2	$3.27M	Buy	33,341 +5,363	+19%	+$472K	0.29%	53
2020 Q1	$2.13M	Buy	27,978 +1,249	+5%	+$106K	0.22%	67
2019 Q4	$2.37M	Sell	26,729 -980	-4%	-$81.4K	0.22%	74
2019 Q3	$2.1M	Buy	27,709 +690	+3%	+$47.3K	0.21%	75
2019 Q2	$1.97M	Buy	27,019 +755	+3%	+$59.3K	0.2%	72
2019 Q1	$2.12M	Sell	26,264 -375	-1%	-$30.7K	0.23%	63
2018 Q4	$2.46M	Sell	26,639 -1,693	-6%	-$149K	0.29%	52
2018 Q3	$2.68M	Buy	28,332 +72	+0.3%	+$6.83K	0.29%	53
2018 Q2	$2.62M	Buy	28,260 +7,455	+36%	+$728K	0.3%	51
2018 Q1	$1.97M	Sell	20,805 -82	-0.4%	-$9.01K	0.24%	57
2017 Q4	$2.02M	Buy	20,887 +6,377	+44%	+$601K	0.25%	60
2017 Q3	$1.29M	Buy	14,510 +20	+0.1%	+$1.52K	0.17%	82
2017 Q2	$1.05M	Buy	14,490 +181	+1%	+$12.2K	0.15%	88
2017 Q1	$933K	Sell	14,309 -1,414	-9%	-$88.9K	0.15%	92
2016 Q4	$984K	Buy	15,723 +390	+3%	+$23.8K	0.17%	85
2016 Q3	$966K	Sell	15,333 -8,986	-37%	-$582K	0.17%	78
2016 Q2	$1.51M	Sell	24,319 -199	-0.8%	-$12.1K	0.28%	54
2016 Q1	$1.4M	Buy	24,518 +1,586	+7%	+$88.4K	0.27%	57
2015 Q4	$1.36M	Sell	22,932 -522	-2%	-$30.1K	0.28%	56
2015 Q3	$1.28M	Buy	23,454 +2,325	+11%	+$151K	0.27%	54
2015 Q2	$1.42M	Buy	21,129 +1,857	+10%	+$121K	0.28%	54
2015 Q1	$1.13M	Buy	19,272 +7,675	+66%	+$464K	0.22%	69
2014 Q4	$758K	Buy	11,597 +58	+0.5%	+$3.66K	0.16%	104
2014 Q3	$666K	Sell	11,539 -1,122	-9%	-$62.3K	0.13%	121
2014 Q2	$714K	Sell	12,661 -637	-5%	-$33.4K	0.14%	120
2014 Q1	$684K	Buy	13,298 +80	+0.6%	+$4.04K	0.14%	126
2013 Q4	$698K	Sell	13,218 -331	-2%	-$16.3K	0.14%	124
2013 Q3	$606K	Sell	13,549 -3,502	-21%	-$155K	0.14%	127
2013 Q2	$705K	Buy	+17,051	New	+$746K	0.17%	110

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Smithfield Trust's ABBV Position: Q1 2026 in Review

Smithfield Trust increased its AbbVie (ABBV) stake by 0.5% in Q1 2026, buying an estimated $35.7K and bringing the position to 32,099 shares worth $6.98M. The position accounts for 0.3% of the portfolio, ranked #55.

Smithfield Trust first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.4M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Smithfield Trust held 32,099 shares of AbbVie worth $6.98M as of Q1 2026.
Smithfield Trust bought 161 AbbVie shares in Q1 2026, an estimated $35.7K.
AbbVie made up 0.3% of Smithfield Trust's portfolio in Q1 2026, its #55 holding.
Smithfield Trust first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Smithfield Trust's AbbVie position peaked at $7.4M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.